包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
Kinase experiment: | Cells (20,000 per well) are grown for 24 h in 96-well plates, then exposed to 2-HBA (bis(2-hydroxybenzylidene)acetone) for either 24 h (for glutathione determination) or 48 h (for determination of enzyme activities). At the end of the exposure period, cells are collected by centrifugation (1500×g for 15 min at 4℃), washed with DPBS, and finally lysed in 0.08% digitonin. An aliquot (25 μL) is used for protein analysis. Activity of NQO1 is determined by the Prochaska test[1]. |
Cell experiment: | After exposure to 2-HBA (bis(2-hydroxybenzylidene)acetone) for 24 h, duplicate aliquots of cells (1×106) are collected by centrifugation and washed with cold DPBS. Apoptosis is determined using the Annexin-V-FLUOS assay with simultaneous determination of the necrotic fraction by the uptake of propidium iodide[1]. |
产品描述 | 2-HBA is an inducer of the Keap1-Nrf2-ARE pathway. Keap1-Nrf2-ARE directly react with Keap1, the sensor protein for inducers, leads to enhanced transcription of phase 2 genes and protection against oxidant and electrophile toxicities. In vitro: 2-HBA could markedly increase the activities of NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1) and glutathione reductase, the levels of total glutathione, as well as the phase 2 response markers. In addition, at high concentrations 2-HBA caused G2/M cell cycle arrest and apoptosis. Moreover, the mutant L1210 cell line was found to be more sensitive to the apoptotic effects of 2-HBA [1]. In vivo: The effect of 2-HBA on the DMBA-induced expression of the Ha-ras gene in isolated RNA tissues of CBA/Ca inbred mice was investigated. According to the previous findings, elevated Ha-ras expression was obserrved even 24 h after DMBA treatment. Administration of 2-HBA with DMBA could lead to a decrease of the DMBA-induced Ha-ras gene expression in all the investigated tissues, suggesting metabolic interaction of 2-HBA and DMBA. In addiiton, administration of 2-HBA 24 h prior to the DMBA treatment was able to reduce the Ha-ras gene expression in all tested tissues except the liver, which could be the result of a possible CYP1A inducer and pro-oxidant effects of 2-HBA [2]. Clinical trial: Up to now, 2-HBA is still in the preclinical development stage. References: |